Search | IOVS | ARVO Journals

Showing 1 – 20 of 27

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2019

In vitro expression model for AAV2.VMD2.BEST1 gene therapy vectors

Cristina Martinez-Fernandez dela Camara; Richard Truran; Gregory Robinson; Robert E MacLaren

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3416. doi:

ARVO Annual Meeting Abstract July 2019

Preserving functional vision through combined treatment of the retina and brain using genetically modified autologous mesenchymal stem cells in a canine model of CLN2 disease

Rebecca Whiting; Grace Robinson; Christopher Tracy; Jacqueline Pearce; Juri Ota-Kuroki; Lauren Gillespie; Leilani Castaner; Joan R. Coates; Martin L Katz

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4485. doi:

ARVO Annual Meeting Abstract July 2019

Contextual visual processing and visual working memory deficits in Alzheimer’s disease

William John Harrison; Jason B Mattingley; Gail A Robinson

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5920. doi:

Retina February 2019

An Evaluation of a Battery of Functional and Structural Tests as Predictors of Likely Risk of Progression of Age-Related Macular Degeneration

PDF

D. Grant Robinson; Tom H. Margrain; Clare Bailey; Alison M. Binns
TAGS: age-related macular degeneration, dark adaptation, outcome measures, photopsia, retinal cone, severity of illness, vision, drusen, retina, eye
Invest. Ophthalmol. Vis. Sci.. 2019; 60(2):580-589. doi: https://doi.org/10.1167/iovs.18-25092

Includes: Supplemental Content

Retina September 2018

Low-Level Nighttime Light Therapy for Age-Related Macular Degeneration: A Randomized Clinical Trial

PDF

D. Grant Robinson; Tom H. Margrain; Matt J. Dunn; Clare Bailey; Alison M. Binns
TAGS: age-related macular degeneration, clinical trials, masks, phototherapy, ultraviolet therapy, outcome measures, drusen, safety, dark adaptation, disease progression
Invest. Ophthalmol. Vis. Sci.. 2018; 59(11):4531-4541. doi: https://doi.org/10.1167/iovs.18-24284

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2018

Intravitreal Enzyme replacement therapy attenuates retinal disease progression in a canine model of neuronal ceroid lipofuscinosis type 2 (CLN2)

John Sinclair; Rebecca Whiting; Grace Robinson; Katherin Bibi; Annalisa Nguyen; Anu Cherukuri; Joshua Henshaw; Gregory de Hart; Chandra Sundeep; Chuck O'Neil; Martin Katz

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):6078. doi:

Physiology and Pharmacology February 2008

Simultaneous but Not Prior Inhibition of VEGF165 Enhances the Efficacy of Photodynamic Therapy in Multiple Models of Ocular Neovascularization

PDF

Meihua Ju; Carolina Mailhos; John Bradley; Tracy Dowie; Mary Ganley; Gary Cook; Perry Calias; Norbert Lange; Anthony P. Adamis; David T. Shima; Gregory S. Robinson
TAGS: cornea, neovascularization, pathologic, pegaptanib, photochemotherapy, sodium, choroidal neovascularization
Invest. Ophthalmol. Vis. Sci.. 2008; 49(2):662-670. doi: https://doi.org/10.1167/iovs.07-0195

Includes: Supplemental Content

ARVO Annual Meeting Abstract May 2007

VEGF-A Plays a Major Retinal Neuroprotective Role in the Adaptive Response to Ischemic Injury

A. P. Adamis; K. Nishijima; Y.-S. Ng; L. Zhong; J. Bradley; W. Schubert; N. Jo; S. J. Samuelsson; G. S. Robinson; D. T. Shima

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):615. doi:

Retina April 2007

Synergies of VEGF Inhibition and Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration

PDF

Maria-Fernanda Zuluaga; Carolina Mailhos; Gregory Robinson; David T. Shima; Robert Gurny; Norbert Lange
TAGS: age-related macular degeneration, anti-vascular endothelial growth factor therapy, photochemotherapy, vascular endothelial growth factor a, vascular occlusion, photosensitizing agents
Invest. Ophthalmol. Vis. Sci.. 2007; 48(4):1767-1772. doi: https://doi.org/10.1167/iovs.06-1224

Glaucoma March 2007

Erythropoietin Promotes Survival of Retinal Ganglion Cells in DBA/2J Glaucoma Mice

PDF

Lichun Zhong; John Bradley; William Schubert; Ednan Ahmed; Anthony P. Adamis; David T. Shima; Gregory S. Robinson; Yin-Shan Ng
TAGS: erythropoietin, glaucoma, mice, retinal ganglion cells, intraocular pressure
Invest. Ophthalmol. Vis. Sci.. 2007; 48(3):1212-1218. doi: https://doi.org/10.1167/iovs.06-0757

Includes: Supplemental Content

ARVO Annual Meeting Abstract May 2006

Intravitreal CAI Inhibits Neovascularization in a Mouse Model of Choroidal Neovascularization (CNV)

S. Palii; S. Caballero, Jr.; S. Jurczyk; A. Franklin; G. Robinson; G. Shapiro; M.B. Grant

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):910. doi:

ARVO Annual Meeting Abstract May 2006

Erythropoietin Promotes Survival of Retinal Ganglion Cells in the DBA/2J Glaucoma Mouse model

L. Zhong; J. Bradley, Sr.; A. Adamis, Sr.; D. Shima; Y.–S. Ng, Sr.; G. Robinson

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):1574. doi:

ARVO Annual Meeting Abstract May 2006

PV–1 Gene Expression Predicts the Loss of Blood Retinal Barrier Function: A Novel Marker of Retinal Vascular Leakage

S.H. Poor; C. Mailhos; J. Bradley; L. Mullin; G.S. Robinson; D.T. Shima

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):502. doi:

ARVO Annual Meeting Abstract May 2006

VEGF Has Both Direct and Indirect Neuroprotective Effects in Ischemic Retina

E. Ng; K. Nishijima; G.S. Robinson; A.P. Adamis; D.T. Shima

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):4829. doi:

ARVO Annual Meeting Abstract May 2006

A Functional Heparin–Binding Domain is Required for Vegf164–Induced Retinal Leukostasis

K. Nishijima; D. Krilleke; G.S. Robinson; A.P. Adamis; Y.–S. Ng; D.T. Shima

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5502. doi:

ARVO Annual Meeting Abstract May 2006

Fenestrae Formation in vitro Provides Clues to Their Biogenesis and Molecular Composition

S. Ioannidou; K. Deinhardt; J. Miotla; J. Bradley; E. Cheung; A. Snodgrass; S. Samuelsson; Y.–S. Ng; G.S. Robinson; D.T. Shima

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5622. doi:

ARVO Annual Meeting Abstract May 2006

Pegaptanib in Combination With Verteporfin–Based PDT Increases Regression of Murine Ocular Neovascularization

M. Ju; C. Mailhos; M. Ganley; T. Dowie; G. Cook; P. Calias; A.P. Adams; N. Lange; G.S. Robinson; D.T. Shima

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):4175. doi:

Biochemistry and Molecular Biology August 2005

Pigment Epithelium–Derived Factor Is a Substrate for Matrix Metalloproteinase Type 2 and Type 9: Implications for Downregulation in Hypoxia

PDF

Luigi Notari; Amanda Miller; Alfredo Martínez; Juan Amaral; Meihua Ju; Gregory Robinson; Lois E. H. Smith; S. Patricia Becerra
TAGS: gelatinase a, hypoxia, matrix metalloproteinases, pigment, proteins, vascular endothelial growth factor a, epithelium, catabolism, gelatin, down-regulation
Invest. Ophthalmol. Vis. Sci.. 2005; 46(8):2736-2747. doi: https://doi.org/10.1167/iovs.04-1489

ARVO Annual Meeting Abstract May 2005

Macugen Efficacy Study in Corneal Neovascularization Model

M. Ju; J. Wing; A. Samuelsson; G. Robinson; C. Mailhos

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):3025. doi:

ARVO Annual Meeting Abstract May 2005

Bilateral Choroidal Detachments Due to Massive Pulmonary Embolism

L. Crawley; A.A. Gurbaxani; G. Robinson; J. Mc Allister

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):5525. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

In vitro expression model for AAV2.VMD2.BEST1 gene therapy vectors

Preserving functional vision through combined treatment of the retina and brain using genetically modified autologous mesenchymal stem cells in a canine model of CLN2 disease

Contextual visual processing and visual working memory deficits in Alzheimer’s disease

An Evaluation of a Battery of Functional and Structural Tests as Predictors of Likely Risk of Progression of Age-Related Macular Degeneration

Low-Level Nighttime Light Therapy for Age-Related Macular Degeneration: A Randomized Clinical Trial

Intravitreal Enzyme replacement therapy attenuates retinal disease progression in a canine model of neuronal ceroid lipofuscinosis type 2 (CLN2)

Simultaneous but Not Prior Inhibition of VEGF165 Enhances the Efficacy of Photodynamic Therapy in Multiple Models of Ocular Neovascularization

VEGF-A Plays a Major Retinal Neuroprotective Role in the Adaptive Response to Ischemic Injury

Synergies of VEGF Inhibition and Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration

Erythropoietin Promotes Survival of Retinal Ganglion Cells in DBA/2J Glaucoma Mice

Intravitreal CAI Inhibits Neovascularization in a Mouse Model of Choroidal Neovascularization (CNV)

Erythropoietin Promotes Survival of Retinal Ganglion Cells in the DBA/2J Glaucoma Mouse model

PV–1 Gene Expression Predicts the Loss of Blood Retinal Barrier Function: A Novel Marker of Retinal Vascular Leakage

VEGF Has Both Direct and Indirect Neuroprotective Effects in Ischemic Retina

A Functional Heparin–Binding Domain is Required for Vegf164–Induced Retinal Leukostasis

Fenestrae Formation in vitro Provides Clues to Their Biogenesis and Molecular Composition

Pegaptanib in Combination With Verteporfin–Based PDT Increases Regression of Murine Ocular Neovascularization

Pigment Epithelium–Derived Factor Is a Substrate for Matrix Metalloproteinase Type 2 and Type 9: Implications for Downregulation in Hypoxia

Macugen Efficacy Study in Corneal Neovascularization Model

Bilateral Choroidal Detachments Due to Massive Pulmonary Embolism

To View More...

You must be signed into an individual account to use this feature.